New Delhi: The Ministry of Health and Family Welfare has proposed adding "antimicrobials" to the definition of a "new drug" under the New Drugs and Clinical Trials Rules, 2019.
If finalised, the change would require manufacturers to obtain permission from the Central Licensing Authority before applying to a State Licensing Authority for a manufacturing licence. The proposal was published in draft notification G.S.R. 983(E), dated November 6, 2026.
The draft proposes inserting the word “antimicrobials” after “monoclonal anti-body” in Rule 2(1)(w)(v), which lists products covered by the definition of a new drug. Under the rule’s explanation, products in this category are always deemed to be new drugs.
The draft stated:
"1. (i) These rules may be called the New Drugs and Clinical Trials (...... Amendment) Rules, 2025.(ii) These rules shall come into force from the date as specified by the Government at the time of final publication of the rules in the Official Gazette.2. In the New Drugs and Clinical Trials Rules, 2019, under the sub-rule (1)(w)(v) of rule 2, after the words “monoclonal anti-body,” the words “antimicrobials,” shall be inserted."
According to the Ministry, the proposal responds to concerns that manufacturing licences for antimicrobial products may be granted without adequate regulatory scrutiny, including assessments such as bioavailability, bioequivalence and stability studies. It said substandard or ineffective antimicrobials could contribute to antimicrobial resistance and pose risks to patients.
The proposed amendment seeks to bring antimicrobials within the regulatory framework applicable to new drugs under the New Drugs and Clinical Trials Rules, 2019. Accordingly, manufacturers would be required to obtain permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the concerned State Licensing Authority (SLA). This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products.
The draft was published after consultation with the Drugs Technical Advisory Board under Sections 12(1) and 33(1) of the Drugs and Cosmetics Act, 1940. The Central Government has invited objections and suggestions within 30 days from the date copies of the Gazette containing the draft are made available to the public. Submissions may be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi–110001, or emailed to drugsdiv-mohfw@gov.in. Press Information Bureau
The proposed change has not yet come into force. The draft says the commencement date will be specified when the final rules are published in the Official Gazette. Although the draft’s proposed rule title ends in “2025”, the notification itself is dated November 6, 2026.
To view the official notice, click the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.